Profile data is unavailable for this security.
About the company
Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.
- Revenue in USD (TTM)0.00
- Net income in USD-53.93m
- Incorporated2011
- Employees11.00
- LocationRenovaro IncCentury City Medical Plaza2080 Century City East, Suite 906LOS ANGELES 90067United StatesUSA
- Phone+1 (212) 763-0184
- Fax+1 (845) 818-3588
- Websitehttps://renovarobio.com/
Mergers & acquisitions
Acquired company | RENB:NAQ since announced | Transaction value |
---|---|---|
Gedi Cube Bv | -56.25% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Elevation Oncology Inc | 0.00 | -39.35m | 209.26m | 29.00 | -- | 2.61 | -- | -- | -1.03 | -1.03 | 0.00 | 1.47 | 0.00 | -- | -- | 0.00 | -42.35 | -- | -46.30 | -- | -- | -- | -- | -- | -- | -12.50 | 0.2889 | -- | -- | -- | 51.93 | -- | -- | -- |
Invivyd Inc | 0.00 | -206.82m | 210.00m | 94.00 | -- | 1.18 | -- | -- | -1.86 | -1.86 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -73.08 | -- | -81.48 | -- | -- | -- | -- | -- | 5.77 | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
Compass Therapeutics Inc. | 0.00 | -45.44m | 210.51m | 32.00 | -- | 1.34 | -- | -- | -0.3513 | -0.3513 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -26.03 | -41.75 | -27.21 | -46.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
Boundless Bio Inc | -100.00bn | -100.00bn | 213.64m | 72.00 | -- | -- | -- | -- | -- | -- | -- | 4.79 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
TriSalus Life Sciences Inc | 21.98m | -68.07m | 214.56m | 112.00 | -- | -- | -- | 9.76 | -2.09 | -2.09 | 0.7291 | -1.31 | 1.17 | 1.26 | 7.49 | 196,276.80 | -339.18 | -- | -11,196.50 | -- | 86.74 | -- | -291.08 | -- | 0.714 | -16.82 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
Werewolf Therapeutics Inc | 16.22m | -41.58m | 215.54m | 46.00 | -- | 1.83 | -- | 13.29 | -1.09 | -1.09 | 0.4343 | 2.72 | 0.087 | -- | 4.61 | 345,127.70 | -22.31 | -- | -25.22 | -- | -- | -- | -256.33 | -- | -- | -- | 0.2511 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
Coherus Biosciences Inc | 301.87m | -59.29m | 215.68m | 249.00 | -- | -- | -- | 0.7145 | -0.7801 | -0.7801 | 2.86 | -0.7211 | 0.5178 | 3.17 | 1.71 | 986,506.60 | -10.17 | -21.43 | -23.51 | -29.32 | 41.46 | 79.01 | -19.64 | -36.56 | 1.05 | -3.87 | 1.21 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
Ovid Therapeutics Inc | 473.53k | -50.68m | 216.38m | 40.00 | -- | 2.76 | -- | 456.95 | -0.7174 | -0.7174 | 0.0067 | 1.11 | 0.0034 | -- | -- | 11,838.25 | -36.86 | -20.78 | -39.08 | -23.27 | -- | -- | -10,701.91 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
Renovaro Inc | 0.00 | -53.93m | 216.83m | 11.00 | -- | 1.29 | -- | -- | -0.7661 | -0.7661 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -37.06 | -27.81 | -41.75 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
2Seventy Bio Inc | 71.20m | -223.22m | 219.50m | 274.00 | -- | 1.06 | -- | 3.08 | -4.34 | -4.34 | 1.39 | 4.04 | 0.1136 | -- | 2.68 | 259,857.70 | -35.62 | -- | -40.00 | -- | 77.68 | 91.76 | -313.51 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
Pyxis Oncology Inc | 16.15m | -57.80m | 220.24m | 51.00 | -- | 1.19 | -- | 13.64 | -1.39 | -1.39 | 0.368 | 3.13 | 0.0801 | -- | -- | 322,920.00 | -28.68 | -- | -30.64 | -- | 97.06 | -- | -358.00 | -- | -- | -- | 0.00 | -- | -- | -- | 38.87 | -- | -- | -- |
Codexis Inc | 74.23m | -65.13m | 222.26m | 174.00 | -- | 2.80 | -- | 2.99 | -0.9412 | -0.9412 | 1.07 | 1.12 | 0.4039 | 5.92 | 4.34 | 426,632.20 | -35.43 | -17.13 | -43.38 | -20.23 | 82.29 | 77.29 | -87.73 | -37.04 | 3.63 | -- | 0.2617 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
AVITA Medical Inc | 50.70m | -44.82m | 222.65m | 207.00 | -- | 6.83 | -- | 4.39 | -1.76 | -1.76 | 1.99 | 1.26 | 0.5336 | 1.48 | 8.39 | 244,913.00 | -47.18 | -- | -53.79 | -- | 85.43 | -- | -88.41 | -- | 6.64 | -19.61 | 0.5591 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
Eliem Therapeutics Inc | 0.00 | -14.53m | 222.84m | 9.00 | -- | 2.00 | -- | -- | -0.5347 | -0.5347 | 0.00 | 3.84 | 0.00 | -- | -- | 0.00 | -12.55 | -- | -13.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
Conduit Pharmaceuticals Inc | -100.00bn | -100.00bn | 223.70m | -- | -- | -- | -- | -- | -- | -- | -- | -0.042 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Akebia Therapeutics Inc | 187.23m | -43.03m | 224.27m | 167.00 | -- | -- | -- | 1.20 | -0.2213 | -0.2213 | 0.9726 | -0.1301 | 0.7454 | 1.34 | 8.43 | 1,121,108.00 | -17.13 | -37.42 | -24.39 | -56.00 | 83.44 | 69.13 | -22.98 | -82.25 | 1.31 | -4.82 | 10.44 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 3.90m | 2.72% |
Geode Capital Management LLCas of 31 Mar 2024 | 437.97k | 0.31% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 373.60k | 0.26% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 306.14k | 0.21% |
Millennium Management LLCas of 31 Mar 2024 | 293.63k | 0.20% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 257.04k | 0.18% |
Citigroup Global Markets, Inc. (Investment Management)as of 31 Mar 2024 | 187.45k | 0.13% |
Susquehanna Financial Group LLLPas of 31 Mar 2024 | 178.09k | 0.12% |
Jane Street Capital LLCas of 31 Mar 2024 | 133.84k | 0.09% |
JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 120.35k | 0.08% |